(2S)-1-[(6S)-6-[6-[2-[4-[2-[(2S)-1-[2-(3-chlorophenyl)propanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-benzimidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-2,3-dimethylbutan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2S)-1-[(6S)-6-[6-[2-[4-[2-[(2S)-1-[2-(3-chlorophenyl)propanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-benzimidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-2,3-dimethylbutan-1-one
• 化学式: C₄₃H₄₅ClN₆O₂
• 分子量: 713.3
• InChiKey: PMECGCDLJFXJTB-PUSYMOIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  52
• 可旋转键数：
  9
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20140193363A1

  公开（公告）日：2014-07-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.